This patent allowance meaningfully de-risks stenoparib’s U.S. commercial pathway and could attract partnership interest. Traders should monitor upcoming clinical data readouts from the ovarian cancer and SCLC trials, which may catalyze re-rating. Consider positioning ahead of potential FDA breakthrough designation or interim results.
Price Chart
Executive Summary
Allarity Therapeutics announced a Notice of Allowance from the USPTO for a patent covering its DRP® companion diagnostic specific to stenoparib, with formal grant expected within three months. The patent will provide U.S. market exclusivity for stenoparib when used with the DRP test at least through 2039, strengthening the company's IP position ahead of potential FDA approval in ovarian cancer. This development enhances the commercial viability of stenoparib, particularly as clinical trials progress in platinum-resistant ovarian cancer and small cell lung cancer.
Key Facts
- USPTO issued a Notice of Allowance for Allarity’s stenoparib DRP® companion diagnostic patent.
- Patent expected to be formally granted within three months and provides U.S. exclusivity at least into 2039.
- Claims cover methods for predicting clinical benefit and selecting patients using gene expression profiles.
- Allarity has ongoing Phase 2 trials in ovarian cancer (amended protocol for platinum-resistant patients) and relapsed SCLC.
- Company holds 18 granted DRP-related patents globally, including 8 in the U.S., with additional applications pending in key markets.
Financial Impact
Significant long-term value enhancement due to extended IP protection; no immediate revenue impact but increases probability of future commercial success.
Risk Factors
- Patent grant is pending final administrative steps and could face delays.
- Clinical trials remain early-stage; failure in Phase 2 would undermine the value of the diagnostic patent.
- Low market cap ($21M) implies high execution risk and vulnerability to dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281537 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $1.04 | awaiting T+20 | — | $0.9430 (−9.33%) |
Sep 29, 2026 28d ago | 8-K | $0.9651 | awaiting T+20 | — | $0.9430 (−2.29%) |
Sep 28, 2026 29d ago | Press Release | $0.9684 $0.9151 | ▼ −5.50% | ▼ −5.47% | $0.9430 (−2.62%) |
Sep 16, 2026 5w ago | 8-K | $1.16 $0.8699 | ▼ −24.68% | ▼ −27.86% | $0.9430 (−18.35%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $0.8601 | ▼ −26.49% | ▼ −28.75% | $0.9430 (−19.40%) |
Sep 11, 2026 6w ago | Press Release | $1.22 $0.9900 | ▼ −18.85% | ▼ −20.72% | $0.9430 (−22.70%) |
Aug 14, 2026 10w ago | Press Release | $1.37 $1.17 | ▼ −14.60% | ▼ −12.61% | $0.9430 (−31.17%) |
Jul 1, 2026 16w ago | 8-K | $1.33 $1.16 | ▼ −12.78% | ▼ −10.60% | $0.9430 (−29.10%) |
Jun 22, 2026 18w ago | 8-K | $1.36 $1.19 | ▼ −12.50% | ▼ −12.35% | $0.9430 (−30.66%) |
Jun 18, 2026 18w ago | Press Release | $1.43 $1.17 | ▼ −18.18% | ▼ −18.71% | $0.9430 (−34.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers